Abstract
Purpose
The coronavirus disease 2019 (COVID-19) vaccine is the key to getting out of the pandemic. However, acceptance of the vaccine has been affected by false information and rumors, which have kept people from getting the shot since it was rolled out.
Materials and Methods
This study aimed to investigate the various misconceptions surfaced about the COVID-19 vaccines in Africa. We performed an online survey using an anonymous questionnaire to reach out to African respondents by social media and all possible online platforms such as Facebook, WhatsApp, Instagram, Twitter, YouTube, and so forth. The web-based questionnaires about the myths surrounding the vaccines were extracted from nonscientific information, unproven statements, social media posts, news reports, and people’s concerns about the safety of the COVID-19 vaccines. Participants indicated their level of agreement with each statement.
Results
A total of 2,500 people responded to the online survey in Africa. The two common myths that respondents agreed with were that “since vaccines for COVID-19 have been developed, we can make vaccines for the common cold, human immunodeficiency viruses, and other diseases” (n=892, 35.7%) and that “researchers rushed the development of the COVID-19 vaccines; therefore, it is not very effective, safe and cannot be trusted” (n=595, 23.8%). The range of respondents who neither agreed nor disagreed with these myths was 12.4%–33.0%. The majority (1,931, 77.2%) indicated disagreement with the statement “after getting the COVID-19 vaccine, one can stop wearing a mask as well as taking safety precautions.”
Conclusion
Myths surrounding the COVID-19 vaccines have impact on acceptance. Exploring them helps public health authorities in Africa dispel them and provide accurate information to promote vaccination campaigns, education, and acceptance.
Keywords: Therapeutic misconception, Patient acceptance of health care, COVID-19 vaccines, Africa
Introduction
Since its emergence in December 2019, the coronavirus disease 2019 (COVID-19) pandemic has threatened the world with high transmission, hospitalizations, and mortality rates [1]. Before the end of December 2020, the pandemic has led to the deaths of more than 1.6 million people across 223 countries around the globe. The whole world was waiting to arrive at an effective and safe vaccine and its strategies to combat the COVID-19 pandemic [2].
Progress in vaccine development was seen in December 2020 when a partnership between the Department of Health and Human Services and Department of Defense which has organized a public-private partnership called “Operation Warp Speed” reported 300+ COVID-19 vaccine candidates, of which 52 were in the phase of clinical evaluation and the remaining been in preclinical development [3]. Eventually, six vaccine candidates showed promising potential in their efficacy proceeded to the phase 3 large-stage clinical trials. Only three gained the Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) Emergency Use Approval in the United States, Moderna, Johnson & Johnson’s Janssen, and Pfizer-BioNTech [4]. Novavax and AstraZeneca are in large-scale (phase 3) clinical trials in the United States [4]. AstraZeneca was approved by the World Health Organization (WHO) and used across the world. Sputnik V-Russia is approved in Central and South America, the Middle East, Central Europe, Africa, Asia, Russia, and Africa.
Vaccination of the global population aimed to promote individual immunity against the deadly virus and protect those unable to get vaccinated through “herd immunity” [5]. It is estimated that 55%–82% vaccine uptake is required to build herd immunity against the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) [6]. The COVAX Global Initiative was established to provide equitable access to COVID-19 vaccines across the world to higher-income and lower-income countries. The WHO, United Nations Children’s Fund, Coalition for Epidemic Preparedness Innovations, Access to COVID-19 Tools ACT-Accelerator, Gavi, the Vaccine Alliance, PAHO Revolving Fund, and the World Bank have delivered over 70 million doses to 126 countries, working with both governments and vaccine manufacturers [7]. The goal is to work with vaccine manufacturers to offer low-cost COVID-19 vaccines to countries. Inovio, Moderna, CureVac, Institute Pasteur/Merck/Themis, AstraZeneca/University of Oxford, Novavax, University of Hong Kong, Clover Biopharmaceuticals, and University of Queensland/CSL are part of the COVAX Initiative. The COVAX Initiative aims to supply 600 million doses to Africa to vaccinate at least 20% of the population. Contributing countries include France, Norway, Germany, Italy, New Zealand, Spain, Sweden, the United Arab Emirates (UAE), Canada, and the United States [7]. Some African countries are also getting vaccine donations from China, Russia, India, and the UAE. The African countries of Tanzania, Burundi, Burkina Faso, Central African Republic, Chad, and Eritrea are yet to receive COVID-19 vaccines [7].
Dr. Seth Berkley, CEO of Gavi, the Vaccine Alliance, stated that “the momentum we are witnessing behind this unprecedented global effort means there could be light at the end of the tunnel: a vaccine is our best route to ending the acute phase of the pandemic, and the COVAX effort is the best way to get there [8]. For higher-income countries, it represents a win-win: not only will you be guaranteed access to the world’s largest portfolio of vaccines, but you will also be negotiating as part of a global consortium, bringing down prices and ensuring truly global access. Signing up to the COVAX Facility gives each country its best chance at protecting the most vulnerable members of their populations—which in turn gives the world its best chance at mitigating the toll this pandemic has taken on individuals, communities, and the global economy. To make this end-to-end vision a reality, we need countries to make end-to-end commitments: funding research and development, signing up to the Facility, and supporting the COVAX Advance Market Commitment.”
Therefore, equal access to a COVID-19 vaccine is the key to beating the virus and paving the way for recovery from the pandemic. COVID-19 vaccination, in combination with prevention and control guidelines such as handwashing and masking-up, remains an important tool to stop the pandemic [9]. As recommended by experts, getting vaccinated will protect people and particularly people at increased risk of severe illness from COVID-19 [9].
Distribution complications and lack of health infrastructure and staff contribute to slow vaccination rates. Nine countries have administered less than a quarter of the doses they obtained, and 15 countries have given less than half of the doses [3]. However, despite public health importance, high mortality, vaccine hesitancy is rising globally due to myths surrounding the COVID-19 vaccines leading to lower than anticipated acceptance. They spread with ease due to social media and online platforms. This widespread misinformation, skepticism, and popularity of anti-vaccine movements toward the COVID-19 vaccination make global vaccination and herd immunity an even more difficult task [10]. “While we call for vaccine equity, Africa must also knuckle down and make the best of what we have,” said Matshidiso Moeti, regional director for WHO in Africa [3].
Previous studies indicate that people have various misconceptions and are likely to reject a newly developed vaccine for a detected disease [11]. The polio vaccine boycott in Nigeria prompted by distrust and fallacies which lead to a five-fold increase in the polio incidence in Nigeria between 2002 and 2006 is an example [12,13]. Subsequently, a mass deworming program was rejected in Ghana due to misconception among community members [14]. Okunlola et al. [15] in 2020 highlighted some myths and misconceptions associated with the COVID-19 pandemic. Although a global survey done by the World Economic Forum in 15 countries showed high vaccination intentions in China (80%), the United Kingdom (77%), and the United States (nearly 70%), there remains robust and widespread movements and resistance to COVID-19 vaccination globally [16]. According to this same study, the number of people who agreed to take the vaccines dropped significantly in some countries, including South Africa and France [2]. Concerns ranged from possible side effects to the speed at which the vaccines were developed and more mysterious allegations that the vaccines contain a microchip for tracking purposes [2]. People also have a mixed feeling of whether the vaccines are safe, protect against the virus, and stop wearing masks after vaccination. Whereas others would accept the vaccines, others will not [17], which may be due to fears, worries, and surrounding misconceptions.
Deliveries of the COVID-19 vaccines in Africa started in February 2021, intending to supply 600 million doses to vaccinate at least 20% of the population under the COVAX Program [18]. It is necessary to identify some of the myths that influence people’s intention not to get vaccinated to effectively develop interventions and health education to promote a positive vaccination attitude and overall acceptance of the COVID-19 vaccines. A study commissioned by the African CDC on COVID-19 vaccine perceptions in 15 countries indicated a significant proportion of people had concerns around vaccine safety. On average, about 20% of respondents said they would not have a vaccine, but the proportion varied from below 10% in Ethiopia, Niger, and Tunisia to 41% in Democratic Republic of the Congo [19]. Assessing the knowledge, attitude and perceptions of respondents, and further education of the general public has proved effective in changing the risk perception of the populace and resulted in attitudinal changes that were necessary to reduce the epidemic disease burden [20]. Adequate monitoring of social media platforms to confirm and improve the quality of information delivered to the people is of prime importance. The present study explores the perceived myths about the safety of vaccines and the impacts of these myths on acceptance in Africa.
Materials and Methods
Study design and questionnaire development
This study employed a cross-sectional approach to recruiting participants through an online survey focusing on Africa. A web-based survey in English was developed using Google Docs for this purpose, and responses were collected in Google Forms database; data collection took place until July 5, 2021. The online survey was disseminated on January 5, 2021, on all online platforms, social media, and targeted groups in Africa’s regions. The responsibility to ensure wide distribution and organization of the data collection process was also entrusted to professional groups situated in all the regions of Africa.
The survey questions were divided into two sections: The first section inquired about the sociodemographic characteristics of respondents and the second section was statements related to the myths of the COVID-19 vaccine. These statements were gathered and reviewed by the study organizers from anti-vaccine groups, social media misinformation, “fake news”, and questions or concerns about the safety of COVID-19 vaccines. Participants’ responses were categorized by agreeing, disagreeing, or expressing no idea about the statements. Respondents were asked whether they would accept the COVID-19 vaccine when made available. The estimated time it took to complete the survey was around 5 minutes. To ensure the appropriateness, preliminary validity, and feasibility of the questionnaires, the survey was reviewed and evaluated by five experts in the field of health education, vaccine development, and health communication related to the statements’ cognitive construction and correct interpretation. A pilot test of the survey with 10% of the participants was carried out to rule out irrelevant statements. The experts suggested that we include open-ended questions to find out more myths respondents might have had.
Participants
The survey was widely distributed to ensure that respondents from all five regions (North, Southern, East, West, and Central) of Africa were represented. No sample size determination method was employed because the study aimed to recruit an adequate number of respondents who will give general objective views about the myths surrounding the COVID-19 vaccines with a more remarkable analysis power.
Inclusion criteria were met by participants by having access to the internet, using a tablet or iPad, and consented to participation in the study. Minors under 18 years of age were excluded from the study because of their vulnerability as a population and additional protections for children in research. Participants were also excluded from the study if their submitted survey responses were incomplete (with 95 responses not included). History of prior vaccination and medical circumstances related to COVID-19 did not affect participation.
Ethical considerations
The study (protocol GHS-ERC 009/02/21) was submitted to the Ghana Health Service Ethics Committee in the host country, where the survey originated and was designed. It was determined that the survey procedures aimed at observing public behavior or involved minimal risk were exempted from ethical review and did not require ethical approval. However, all procedures employed in this study were in line with the medical research ethical principles of the World Medical Association Declaration of Helsinki. The purpose and details of the study were fully explained to the participants through the introductory page and the consent form contained within the online survey. Participation was voluntary, and the surveys were completely anonymous with no names, no confidential details, or identifiable information required.
Statistical analysis
The data collected were coded and entered into Microsoft Excel (Microsoft Corp., Redmond, WA, USA) for data cleaning and labeling. Responses to each statement were grouped as agree, neutral (no idea), and disagree. Data analysis was performed using IBM SPSS Statistics ver. 24.0 (IBM Corp., Armonk, NY, USA). Demographic variables were obtained using frequencies and percentages. Five age groups were defined for this study: 18–29, 21–30, 31–40, 41–50, and 51 years and above. All comparisons were made using the chi-square test of association. Statistical significance was set to be p<0.05.
Results
A total of 2,500 responses were included and analyzed for the study. Incomplete submissions such as respondents skipping specific questions and minor omissions were excluded and not considered part of the data analyzed. Almost two-thirds (61.3%) of the respondents were females, while 38.7% were males. Ages ranged from 18 years to 51 years and above, with the age group of 21–30 years forming most respondents (35.8%). Among the participants, 90.7% reported that they had attained high education, whereas 64.8% were employed. Approximately 40% of the respondents (980/2,500) were from West Africa, 665 Central Africans, 450 East Africans, 235 Southern Africans, and 170 North Africa participants. Table 1 presents the details of respondents on age, marital status, religion, education, and occupational status. Table 2 shows a statistically significant association between demographic variables such as gender, age, marital status, religion, high education attainment, occupation status, access to credible information, and the acceptance of COVID-19 vaccines or the vaccine’s acceptance dependent on these demographic variables.
Table 1. Demographic characteristics of the respondents.
Characteristic | No. (%) | |
---|---|---|
Gender | ||
Male | 967 (38.7) | |
Female | 1,533 (61.3) | |
Age (yr) | ||
18–20 | 104 (4.2) | |
21–30 | 895 (35.8) | |
31–40 | 631 (25.2) | |
41–50 | 385 (15.4) | |
≥51 | 485 (19.4) | |
Marital status | ||
Single | 1,140 (45.6) | |
Married | 1,116 (44.6) | |
Co-habitation/relationship | 206 (18.2) | |
Separated/divorced | 38 (1.5) | |
Religion | ||
Christian | 1,766 (70.6) | |
Muslim | 337 (13.5) | |
Traditional and others | 397 (15.9) | |
Occupation status | ||
Employed | 1,621 (64.8) | |
Unemployed | 879 (35.2) | |
Attained higher education | ||
Yes | 2,267 (90.7) | |
No | 233 (9.3) | |
African sub-region of respondents | ||
West Africa | 980 (39.2) | |
East Africa | 450 (18.0) | |
Central Africa | 665 (26.6) | |
North Africa | 170 (6.8) | |
Southern Africa | 235 (9.4) | |
Accept vaccine | ||
Yes | 1,699 (68.0) | |
No | 801 (32.0) |
Table 2. Association between selected demographic variables with acceptance of the coronavirus disease 2019 vaccines (n=2,500).
Variable | Acceptance of the COVID-19 vaccines | df | χ2 (Fischer's exact test) | p-value | ||
---|---|---|---|---|---|---|
No | Yes | |||||
Gender | ||||||
Female | 448 | 1,081 | 1 | 16.833 | 0.001* | |
Male | 361 | 610 | ||||
Age (yr) | ||||||
18–20 | 56 | 56 | 4 | 44.310 | < 0.001 | |
21–30 | 322 | 639 | ||||
31–40 | 208 | 399 | ||||
41–50 | 126 | 237 | ||||
≥51 | 97 | 360 | ||||
Marital status | ||||||
Single | 404 | 819 | 3 | 100.231 | < 0.001 | |
Married | 266 | 775 | ||||
Co-habitation/relationship | 111 | 84 | ||||
Separated/divorced | 28 | 13 | ||||
Religion | ||||||
Christian | 601 | 1,136 | 2 | 17.130 | 0.008 | |
Muslim | 112 | 251 | ||||
Traditional and others | 96 | 304 | ||||
Higher education attainment | ||||||
Not attained | 168 | 69 | 1 | 177.542 | < 0.001* | |
Attained | 641 | 1,622 | ||||
Occupational status | ||||||
Employed | 406 | 1,150 | 1 | 73.952 | < 0.001* | |
Unemployed | 403 | 541 | ||||
Regular access to credible information | ||||||
No access | 237 | 125 | 1 | 212.001 | < 0.001* | |
Have access | 572 | 1,566 |
df, degrees of freedom.
*p<0.05 level of significance.
Ten statements were presented to the respondents, and their responses to each of them are shown in Table 3. Agreement with these statements ranged from 8.8%–35.7%. The range in percentage of respondents who expressed “no idea (neutral stands)” with each statement was 12.4%–33.0%. The statements that a few respondents agreed with were that “since vaccines for the COVID-19 have been developed, we can make vaccines for the common cold, human immunodeficiency viruses (HIV) and others” (35.7%) and that “researchers rushed the development of the COVID-19 vaccines; therefore, it is not very effective and safe or cannot be trusted” (23.8%). However, most respondents debunked and disagreed with some of these myths. The majority (77.2%) did not agree that after getting the COVID-19 vaccines, one can stop wearing a mask and taking safety precautions. Consequently, 66.4% do not believe that the COVID-19 vaccine enters your cell and changes the DNA. Respondents who will accept the vaccine were more likely to disagree with statements 1, 2, 3, 4, 5, 6, 7, 9, and 10, whereas those who will not take the vaccine agreed (p=0.001). The present study also identified that certain myths about the COVID-19 vaccines do not influence acceptance shown in Table 4. The myth did not influence acceptance that since vaccines for COVID-19 have been developed, “we can make vaccines for other viruses such as the common cold and HIV [21].”
Table 3. Responses of Africans to the myths surrounding the COVID-19 vaccines.
Statements | Response | ||
---|---|---|---|
Agree | Neutral (no idea) | Disagree | |
1. Taking the COVID-19 vaccine can make me sick with COVID-19. | 389 (15.6) | 492 (19.7) | 1,619 (64.8) |
2. The COVID-19 vaccines affect fertility or prevent having a baby later in life for a woman. | 273 (10.9) | 826 (33.0) | 1,401 (56.0) |
3. If I have had the COVID-19 infection and recovered, I don't need the vaccine. | 401 (16.0) | 451 (18.0) | 1,648 (65.9) |
4. Researchers rushed the development of the COVID-19 vaccines; therefore, it is not very effective and safe or cannot be trusted. | 595 (23.8) | 581 (23.2) | 1,324 (53.0) |
5. After getting the COVID-19 vaccine, one can stop wearing the mask and taking safety precaution. | 221 (8.8) | 348 (13.9) | 1,931 (77.2) |
6. The side effects of the vaccines are dangerous and include allergic reactions so that I won't take the vaccines. | 442 (17.7) | 670 (26.8) | 1,388 (55.5) |
7. The COVID-19 vaccines enters your cells and change your DNA. | 312 (12.5) | 529 (21.2) | 1,659 (66.4) |
8. Since vaccines for the COVID-19 have been developed, we can make vaccines for the common cold, HIV, and others. | 892 (35.7) | 668 (26.7) | 940 (37.6) |
9. The COVID-19 vaccines include a tracking device attached to many mysteries. | 325 (13.0) | 673 (26.9) | 1,502 (60.1) |
10. I am not at risk for COVID-19 infection and its complications. Because of that, there is no need for me to take the vaccines. | 311 (12.4) | 309 (12.4) | 1,880 (75.2) |
Values are presented as number (%).
COVID-19, coronavirus disease 2019; HIV, human immunodeficiency viruses.
Table 4. Potential influence of these statements and their impacts on acceptance of the vaccine.
Variable | Will accept the vaccine | χ2 | df | p-value | ||
---|---|---|---|---|---|---|
No | Yes | |||||
1. Taking the COVID-19 vaccine can make me sick with COVID-19. | ||||||
Agree | 273 | 116 | 454.877 | 2 | 0.001 | |
Neutral (no idea) | 233 | 259 | ||||
Disagree | 295 | 1,324 | ||||
2. The COVID-19 vaccines affect fertility or prevent having a baby later for a woman. | ||||||
Agree | 234 | 39 | 570.631 | 2 | 0.001 | |
Neutral (no idea) | 347 | 479 | ||||
Disagree | 220 | 1,181 | ||||
3. If I have had the COVID-19 infection and recovered, I don’t need the vaccine. | ||||||
Agree | 328 | 78 | 595.642 | 2 | 0.001 | |
Neutral (no idea) | 181 | 270 | ||||
Disagree | 297 | 1,351 | ||||
4. Researchers rushed the development of the COVID-19 vaccines; therefore, it is not very effective and safe or cannot be trusted. | ||||||
Agree | 440 | 155 | 732.285 | 2 | 0.001 | |
Neutral | 205 | 376 | ||||
Disagree | 156 | 1,168 | ||||
5. After getting the COVID-19 vaccine, one can stop wearing the mask and taking safety precaution. | ||||||
Agree | 91 | 130 | 247.176 | 2 | 0.001 | |
Neutral (no idea) | 232 | 116 | ||||
Disagree | 478 | 1,453 | ||||
6. The side effects of the vaccines are dangerous and include allergic reactions so that I won’t take the vaccines. | ||||||
Agree | 351 | 91 | 910.661 | 2 | 0.001 | |
Neutral | 334 | 336 | ||||
Disagree | 116 | 1,272 | ||||
7. The COVID-19 vaccines enters your cells and change your DNA. | ||||||
Agree | 221 | 91 | 442.192 | 2 | 0.001 | |
Neutral (no idea) | 271 | 258 | ||||
Disagree | 309 | 1,350 | ||||
8. Since vaccines for the COVID-19 have been developed, we can make vaccines for the common cold, HIV, and others. | ||||||
Agree | 297 | 595 | 4.158 | 2 | 0.125 | |
Neutral | 193 | 475 | ||||
Disagree | 311 | 625 | ||||
9. The COVID-19 vaccines include a tracking device attached to many mysteries. | ||||||
Agree | 221 | 104 | 428.275 | 2 | 0.001 | |
Neutral | 324 | 349 | ||||
Disagree | 256 | 1,246 | ||||
10. I am not at risk for COVID-19 infection and its complications. Because of that, there is no need for me to take the vaccines. | ||||||
Agree | 285 | 26 | 833.473 | 2 | 0.001 | |
Neutral | 194 | 115 | ||||
Disagree | 322 | 1,558 |
df, degrees of freedom; COVID-19, coronavirus disease 2019; HIV, human immunodeficiency viruses.
Discussion
Hesitancy to new vaccines, population confidence or willingness to vaccinate, and their blunt refusal may be as a result of misinformation about its safety or misconceptions which have gain ground on social media platforms [22,23]. Anti-vaccine lobbyists and religious groups make use of social media and the internet to express and spread their lack of trust in the pharmaceutical industry, advocate against vaccination, and report the alleged risk of vaccination [24,25]. These sometimes justify the myths surrounding the COVID-19 vaccines. Therefore communication, the internet, and social media are paramount to the determinants of vaccine acceptance, hesitancy, and levels of misconceptions.
The present-day study showed that only a tiny percentage of respondents agreed with the myths surrounding the COVID-19 vaccines suggesting only a minority of Africans held significant misconceptions about the vaccines. The study, however, also revealed that one-third of all the respondents (33.0%) neither agreed nor disagreed with the statement that the COVID-19 vaccines affected fertility later in life for women; this implies a lack of knowledge about the COVID-19 vaccines and fertility. It offers an excellent opportunity for stakeholders and health authorities to provide comprehensive information about the possible impact of the vaccine on fertility, pregnancy, and miscarriage. People need to consider the facts about the vaccines and what could happen if they develop COVID-19 symptoms during pregnancy. Couples have to be reassured that it is safe to become pregnant after the COVID-19 vaccination. The vaccine is not causing any change in infertility for women, and unvaccinated expectant mothers have an increased risk of severe illnesses from COVID-19. A study done by Gray et al. [26] in 2021 published in the American Journal of Obstetrics and Gynecology shows that the COVID-19 vaccines are safe and effective for pregnant and breastfeeding women and they also offer protection for their babies. The CDC, the Society for Maternal-Fetal Medicine, and the American College of Obstetricians and Gynecologists agree that the COVID-19 vaccine can be offered to pregnant women who are eligible [27,28,29].
For respondents who still have doubts and safety concerns, they should discuss the risks and benefits of the COVID-19 vaccination with their healthcare providers. There is no evidence that antibodies from the vaccines interfere with fertility or cause pregnancy problems.
We also found some skepticism about whether vaccines for the common cold, HIV, and other diseases can equally be produced since vaccines for the COVID-19 have been developed, which was the most common misconception (35.7%) the study revealed, or participants agreed on. However, it does not significantly affect acceptance. Again, public health authorities need to educate the general population on the logic behind developing the COVID-19 vaccine compared to other diseases. Each disease and the illnesses they cause have their unique challenges, which are different from one another.
Furthermore, respondents were also concerned that researchers rushed the development of the COVID-19 vaccines, and it is not very safe, effective, and trusted. Although the COVID-19 vaccines seemed to have had rapid development, 69 days to clinical trial once developed from laboratory and animal models [30]. The clinical trials that examined the vaccines’ safety and quality control were not rushed or compromised in any way, they used standard vaccine development stages, and they occurred in the United States, Europe, and China [31].
In the past, vaccine development was lengthier partly because of limited technology and resources.
The messenger RNA (mRNA)-based technology is a relatively easy, low-cost manufacturing process, synthetic, and quick to produce [32]. Allows the ability to streamline vaccine discovery and development and facilitate a rapid response to emerging infectious diseases, such as COVID-19 [33]. The technology employed to manufacture the mRNA COVID-19 vaccines was developed in record time because other researchers have been working on mRNA research for three decades [34]. The lessons from this strategy over time were applied for the development for use as COVID-19 vaccines [33].
Experts continuously monitor the safety and standards of the COVID-19 vaccines, scientists worldwide, and agency partners experts to ensure that the COVID-19 vaccines continue to be safe through the CDC, the National Institutes of Health, and the National Academies of Sciences, Engineering, and Medicine. The FDA regulates and approves vaccines in the United States. Vaccines undergo a rigorous review of laboratory, clinical, and manufacturing data to ensure the safety, effectiveness, and quality of these products. The European Medicines Agency (EMA) are the scientific evaluators, approvers, and monitors of vaccines in the European Union, The Medicines and Healthcare Products Regulatory Agency in the United Kingdom [35]. In Africa, Nigerian National Agency for Food and Drug Administration and Control and the South African Health Products Regulatory Authority utilize the FDA and EMA guidance [36].
The FDA Ghana utilizes an independent committee of experts, the Joint COVID-19 Vaccine Safety Review Committee, and an FDA Safety Monitoring Department [37]. It is common for new vaccines to be met with misconceptions and initial hesitancy. One of the considerable sources where African health institutions can give information about the benefits of the COVID-19 vaccines to the general population and recommendations is through social media. Although social media represent a rapidly evolving global environment for disseminating misconceptions, it can be used as a tool for designing an effective educational intervention. This will serve the purpose of increasing vaccine acceptance, addressing hesitancy, and tackling the problem of misinformation in Africa. In this study, the willingness to accept the COVID-19 vaccine among Africans was relatively high as 68% of the respondents expressed the intention to take it regardless of these misconceptions. Demographic profiles such as gender (p=0.001), age (p<0.001), marital status (p<0.001), religion (p=0.008), high educational attainment (p<0.001), occupational status (p<0.001), and access to regular information (p<0.001) were some factors highly associated with acceptance of the vaccine. These demographic characteristics were more likely to contribute to the acceptance of the vaccines or can be regarded as highly accurate predictors of acceptance (Table 5).
Table 5. Analysis of demographic characteristics to the 10 statements.
Statements | Response | p-value | ||||
---|---|---|---|---|---|---|
Agree | Neutral (no idea) | Disagree | ||||
1. Taking the COVID-19 vaccine can make me sick with COVID-19. | 389 (15.6) | 492 (19.7) | 1,619 (64.8) | |||
Gender | ||||||
Female | 259 | 949 | 325 | 0.001 | ||
Male | 130 | 670 | 167 | |||
Age (yr) | ||||||
18–20 | 39 | 52 | 13 | |||
21–30 | 65 | 583 | 247 | |||
31–40 | 117 | 410 | 104 | |||
41–50 | 103 | 218 | 64 | |||
≥51 | 65 | 356 | 64 | |||
Marital status | ||||||
Single | 143 | 279 | 725 | |||
Married | 142 | 181 | 793 | |||
Co-habitation | 78 | 39 | 89 | |||
Separated | 26 | 0 | 12 | |||
Occupation | ||||||
Employed | 220 | 259 | 1,142 | 0.0001 | ||
Unemployed | 169 | 233 | 477 | |||
Attained higher education | ||||||
Yes | 298 | 453 | 1,516 | 0.0001 | ||
No | 91 | 39 | 103 | |||
Religion | ||||||
Christians | 194 | 441 | 1,131 | 0.0001 | ||
Muslims | 104 | 26 | 207 | |||
Traditional and others | 91 | 25 | 281 | |||
2. The COVID-19 vaccines affect fertility or prevent having a baby later in life for a woman. | 273 (10.9) | 826 (33.0) | 1,401 (56.0) | |||
Gender | ||||||
Female | 169 | 517 | 847 | 0.594 | ||
Male | 104 | 309 | 554 | |||
Age (yr) | ||||||
18–20 | 39 | 39 | 26 | 0.0001 | ||
21–30 | 65 | 377 | 453 | |||
31–40 | 65 | 232 | 334 | |||
41–50 | 78 | 76 | 231 | |||
≥51 | 26 | 102 | 357 | |||
Marital status | ||||||
Single | 117 | 467 | 556 | 0.0001 | ||
Married | 91 | 308 | 717 | |||
Co-habitation | 39 | 51 | 116 | |||
Separated | 26 | 0 | 12 | |||
Occupation | ||||||
Employed | 130 | 476 | 1,015 | 0.0001 | ||
Unemployed | 143 | 350 | 386 | |||
Attained higher education | ||||||
Yes | 195 | 761 | 1,311 | 0.0001 | ||
No | 78 | 65 | 90 | |||
Religion | ||||||
Christianity | 169 | 594 | 1,003 | 0.0001 | ||
Muslim | 78 | 104 | 155 | |||
Traditional and others | 26 | 128 | 243 | |||
3. If I have had the COVID-19 infection and recovered, I don’t need the vaccine. | 401 (16.0) | 451 (18.0) | 1,648 (65.9) | |||
Gender | ||||||
Female | 246 | 231 | 1,056 | 0.0001 | ||
Male | 155 | 220 | 592 | |||
Age (yr) | ||||||
18–20 | 0 | 39 | 65 | |||
21–30 | 195 | 91 | 609 | |||
31–40 | 65 | 181 | 385 | |||
41–50 | 77 | 51 | 257 | |||
≥51 | 64 | 89 | 332 | |||
Marital status | ||||||
Single | 181 | 194 | 0.0001 | |||
Married | 116 | 244 | ||||
Co-habitation | 78 | 13 | ||||
Separated | 26 | 0 | ||||
Occupation | ||||||
Employed | 194 | 270 | 1,157 | 0.0001 | ||
Unemployed | 207 | 181 | 491 | |||
Attained higher education | ||||||
Yes | 349 | 412 | 1,506 | 0.023 | ||
No | 52 | 39 | 142 | |||
Religion | ||||||
Christianity | 259 | 311 | 1,196 | 0.0001 | ||
Islam | 78 | 104 | 155 | |||
Traditional and others | 64 | 36 | 297 | |||
4. Researchers rushed the development of the COVID-19 vaccines; therefore, it is not very effective and safe or cannot be trusted. | 595 (23.8) | 581 (23.2) | 1,324 (53.0) | |||
Gender | ||||||
Female | 298 | 362 | 873 | 0.0001 | ||
Male | 297 | 219 | 451 | |||
Age (yr) | ||||||
18–20 | 13 | 13 | 78 | 0.0001 | ||
21–30 | 247 | 286 | 362 | |||
31–40 | 155 | 129 | 347 | |||
41–50 | 129 | 37 | 219 | |||
≥51 | 51 | 116 | 318 | |||
Marital status | ||||||
Single | 272 | 338 | 530 | 0.0001 | ||
Married | 258 | 191 | 667 | |||
Co-habitation | 39 | 56 | 115 | |||
Separated | 26 | 0 | 12 | |||
Occupation | ||||||
Employed | 336 | 360 | 925 | 0.0001 | ||
Unemployed | 259 | 221 | 399 | |||
Attained higher education | ||||||
Yes | 479 | 542 | 1,246 | 0.0001 | ||
No | 116 | 39 | 78 | |||
Religion | ||||||
Christianity | 440 | 439 | 887 | 0.0001 | ||
Islam | 91 | 78 | 168 | |||
Tradition and others | 64 | 64 | 267 | |||
5. After getting the COVID-19 vaccine, one can stop wearing the mask and taking safety precaution. | 221 (8.8) | 348 (13.9) | 1,931 (77.2) | |||
Gender | ||||||
Female | 117 | 143 | 1,273 | 0.0001 | ||
Male | 104 | 205 | 658 | |||
Age (yr) | ||||||
18–20 | 0 | 39 | 65 | |||
21–30 | 156 | 78 | 661 | |||
31–40 | 39 | 65 | 527 | |||
41–50 | 13 | 115 | 257 | |||
≥51 | 13 | 51 | 421 | |||
Marital status | ||||||
Single | 156 | 142 | 842 | 0.0001 | ||
Married | 52 | 154 | 910 | |||
Co-habitation | 13 | 26 | 167 | |||
Separated | 0 | 26 | 12 | |||
Occupation | ||||||
Employed | 0.0001 | |||||
Unemployed | ||||||
Attained higher education | ||||||
Yes | 195 | 296 | 1,776 | 0.0001 | ||
No | 26 | 52 | 155 | |||
Religion | ||||||
Christianity | 117 | 297 | 1,352 | 0.0001 | ||
Islam | 78 | 39 | 220 | |||
Traditional and others | 26 | 12 | 359 | |||
6. The side effects of the vaccines are dangerous and include allergic reactions so that won’t take the vaccines. | 442 (17.7) | 670 (26.8) | 1,388 (55.5) | |||
Gender | ||||||
Female | 221 | 400 | 912 | 0.0001 | ||
Male | 221 | 270 | 476 | |||
Age (yr) | ||||||
18–20 | 13 | 26 | 65 | 0.0001 | ||
21–30 | 169 | 338 | 388 | |||
31–40 | 78 | 168 | 385 | |||
41–50 | 143 | 49 | 195 | |||
≥51 | 39 | 89 | 357 | |||
Marital status | ||||||
Single | 156 | 428 | 556 | 0.0001 | ||
Married | 221 | 177 | 718 | |||
Co-habitation | 39 | 65 | 102 | |||
Separated | 26 | 0 | 12 | |||
Occupation | ||||||
Employed | 234 | 359 | 1,028 | 0.0001 | ||
Unemployed | 208 | 311 | 360 | |||
Attained higher education | ||||||
Yes | 351 | 631 | 1,285 | 0.0001 | ||
No | 91 | 39 | 103 | |||
Religion | ||||||
Christianity | 325 | 503 | 938 | 0.0001 | ||
Islam | 104 | 91 | 142 | |||
Tradition and others | 13 | 76 | 308 | |||
7. The COVID-19 vaccines enters your cells and change your DNA. | 312 (12.5) | 529 (21.2) | 1,659 (66.4) | |||
Gender | ||||||
Female | 156 | 285 | 1,092 | 0.0001 | ||
Male | 156 | 244 | 567 | |||
Age (yr) | ||||||
18–20 | 26 | 26 | 52 | 0.0001 | ||
21–30 | 65 | 246 | 584 | |||
31–40 | 91 | 142 | 398 | |||
41–50 | 104 | 38 | 243 | |||
≥51 | 26 | 77 | 382 | |||
Marital status | ||||||
Single | 117 | 336 | 687 | 0.0001 | ||
Married | 130 | 154 | 832 | |||
Co-habitation | 39 | 39 | 128 | |||
Separated | 26 | 0 | 12 | |||
Occupation | ||||||
Employed | 156 | 271 | 1,194 | 0.0001 | ||
Unemployed | 156 | 258 | 465 | |||
Attained higher education | ||||||
Yes | 234 | 477 | 1,556 | |||
No | 78 | 52 | 103 | |||
Religion | ||||||
Christianity | ||||||
Islam | ||||||
Tradition and others | ||||||
8. Since vaccines for the COVID-19 have been developed, we can make vaccines for the common cold, HIV, and others. | 892 (35.7) | 668 (26.7) | 940 (37.6) | |||
Gender | ||||||
Female | 621 | 372 | 540 | 0.0001 | ||
Male | 271 | 296 | 400 | |||
Age (yr) | ||||||
18–20 | 26 | 39 | 39 | 0.0001 | ||
21–30 | 377 | 233 | 285 | |||
31–40 | 231 | 169 | 231 | |||
41–50 | 103 | 127 | 155 | |||
≥51 | 155 | 100 | 230 | |||
Marital status | ||||||
Single | 364 | 362 | 414 | 0.0001 | ||
Married | 438 | 280 | 398 | |||
Co-habitation | 78 | 28 | 102 | |||
Separated | 12 | 0 | 26 | |||
Occupation | ||||||
Employed | 581 | 462 | 578 | 0.006 | ||
Unemployed | 311 | 206 | 362 | |||
Attained higher education | ||||||
Yes | 581 | 462 | 578 | 0.0001 | ||
No | 311 | 206 | 362 | |||
Religion | ||||||
Christianity | 671 | 488 | 607 | 0.0001 | ||
Islam | 156 | 78 | 103 | |||
Traditional and others | 65 | 102 | 203 | |||
9. The COVID-19 vaccines include a tracking device attached to many mysteries. | 325 (13.0) | 673 (26.9) | 1,502 (60.1) | |||
Gender | ||||||
Female | 234 | 427 | 872 | 0.0001 | ||
Male | 91 | 246 | 630 | |||
Age (yr) | ||||||
18–20 | 39 | 52 | 13 | 0.0001 | ||
21–30 | 156 | 260 | 479 | |||
31–40 | 65 | 169 | 397 | |||
41–50 | 52 | 103 | 230 | |||
≥51 | 13 | 89 | 383 | |||
Marital status | ||||||
Single | 169 | 403 | 568 | 0.0001 | ||
Married | 65 | 244 | 807 | |||
Co-habitation | 65 | 26 | 115 | |||
Separated | 26 | 0 | 12 | |||
Occupation | ||||||
Employed | 104 | 335 | 1,182 | 0.0001 | ||
Unemployed | 221 | 338 | 320 | |||
Attained higher education | ||||||
Yes | 260 | 569 | 1,438 | |||
No | 65 | 104 | 64 | |||
Religion | ||||||
Christianity | 234 | 466 | 1,066 | 0.0001 | ||
Islam | 78 | 143 | 116 | |||
Traditional and others | 13 | 64 | 230 | |||
10. I am not at risk for COVID-19 infection and its complications. Because of that, there is no need for me to take the vaccines. | 311 (12.4) | 309 (12.4) | 1,880 (75.2) | |||
Gender | ||||||
Female | 182 | 143 | 1,208 | 0.0001 | ||
Male | 129 | 166 | 672 | |||
Age (yr) | ||||||
18–20 | 26 | 13 | 65 | 0.0001 | ||
21–30 | 78 | 129 | 688 | |||
31–40 | 104 | 52 | 475 | |||
41–50 | 65 | 63 | 257 | |||
≥51 | 38 | 52 | 395 | |||
Marital status | ||||||
Single | 116 | 142 | 882 | 0.0001 | ||
Married | 143 | 128 | 842 | |||
Co-habitation | 26 | 39 | 141 | |||
Separated | 26 | 0 | 12 | |||
Occupation | ||||||
Employed | 130 | 154 | 1,337 | 0.0001 | ||
Unemployed | 181 | 156 | 543 | |||
Attained higher education | ||||||
Yes | 272 | 270 | 1,725 | 0.006 | ||
No | 39 | 39 | 155 | |||
Religion | ||||||
Christianity | 234 | 218 | 1,314 | 0.001 | ||
Islam | 52 | 39 | 246 | |||
Traditional and others | 25 | 52 | 320 |
Values are presented as number (%) or number.
COVID-19, coronavirus disease 2019; HIV, human immunodeficiency viruses.
These findings corroborate the studies of Al-Mohaithef and Padhi [38] in 2020, who investigated the community determinants that influence COVID-19 vaccine acceptance in Saudi Arabia.
Health education interventions should target sociodemographic groups or areas in Africa that are identified as a priority to increase vaccine/health education, understanding, dispel misconceptions around vaccine safety and increase overall vaccine acceptance. Many people will need to accept and receive COVID-19 vaccines to achieve herd immunity, slow the spread and stop the pandemic in Africa. Globally, 150 doses have been administered per 1,000 people, but it’s about eight doses per 1,000 people in Africa. In South Africa, 67% of its population, 40 million people would need to be fully vaccinated to achieve her immunity by the end of 2021 [39]. Therefore, public health authorities across Africa must provide accurate information focusing on correcting the present study’s misconceptions, promoting positive attitudes, increasing safety awareness, and accepting the COVID-19 vaccines in vaccine campaigns.
The study reflects the views of African respondents on social media with internet access. There could be alternative opinions that were not represented.
Footnotes
No potential conflict of interest relevant to this article was reported.
References
- 1.Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020;20:773. doi: 10.1016/S1473-3099(20)30195-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383:1544–1555. doi: 10.1056/NEJMoa2024671. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.World Health Organization. COVID-19 vaccine tracker and landscape [Internet] Geneva: World Health Organization; 2021. [cited 2021 Mar 7]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines . [Google Scholar]
- 4.Centers for Disease Control and Prevention. About COVID-19 vaccines [Internet] Atlanta (GA): Centers for Disease Control and Prevention; 2021. [cited 2021 May 27]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html#about-vaccines . [Google Scholar]
- 5.Betsch C, Bohm R, Korn L, Holtmann C. On the benefits of explaining herd immunity in vaccine advocacy. Nat Hum Behav. 2017;1:0056 [Google Scholar]
- 6.Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020;26:1470–1477. doi: 10.3201/eid2607.200282. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Craven J. COVID-19 vaccine tracker [Internet] Rockville (MD): Regulatory Affairs Professionals Society; [[date unknown]]. [cited 2021 Jul 9]. Available from: https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker . [Google Scholar]
- 8.World Health Organization. 172 Countries and multiple candidate vaccines engaged in COVID-19 vaccine Global Access Facility [Internet] Geneva: World Health Organization; 2020. [cited 2021 Jul 9]. Available from: https://www.who.int/news/item/24-08-2020-172-countries-and-multiple-candidate-vaccines-engaged-in-covid-19-vaccine-global-access-facility . [Google Scholar]
- 9.Centers for Disease Control and Prevention. Benefits of getting vaccinated [Internet] Atlanta (GA): Centers for Disease Control and Prevention; [cited 2021 Jul 9]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html . [Google Scholar]
- 10.Praveen SV, Ittamalla R, Deepak G. Analyzing the attitude of Indian citizens towards COVID-19 vaccine: a text analytics study. Diabetes Metab Syndr. 2021;15:595–599. doi: 10.1016/j.dsx.2021.02.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Chou WS, Budenz A. Considering emotion in COVID-19 vaccine communication: addressing vaccine hesitancy and fostering vaccine confidence. Health Commun. 2020;35:1718–1722. doi: 10.1080/10410236.2020.1838096. [DOI] [PubMed] [Google Scholar]
- 12.Afolabi AA, Ilesanmi OS. Dealing with vaccine hesitancy in Africa: the prospective COVID-19 vaccine context. Pan Afr Med J. 2021;38:3. doi: 10.11604/pamj.2021.38.3.27401. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Jegede AS. What led to the Nigerian boycott of the polio vaccination campaign? PLoS Med. 2007;4:e73. doi: 10.1371/journal.pmed.0040073. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Febir LG, Asante KP, Dzorgbo DB, Senah KA, Letsa TS, Owusu-Agyei S. Community perceptions of a malaria vaccine in the Kintampo districts of Ghana. Malar J. 2013;12:156. doi: 10.1186/1475-2875-12-156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Okunlola MA, Lamptey E, Senkyire EK, Dorcas S, Dooshima BA. Perceived myths and misconceptions about the novel COVID-19 outbreak. SciMed J. 2020;2:108–117. [Google Scholar]
- 16.Ipsos. US and UK are optimistic indicators for COVID-19 vaccination uptake [Internet] Paris: Ipsos; 2020. [cited 2021 Jul 9]. Available from: https://www.ipsos.com/en/global-attitudes-covid-19-vaccine-december-2020 . [Google Scholar]
- 17.Detoc M, Bruel S, Frappe P, Tardy B, Botelho-Nevers E, Gagneux-Brunon A. Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. Vaccine. 2020;38:7002–7006. doi: 10.1016/j.vaccine.2020.09.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Mwai P. COVID-19 vaccinations: African nations miss WHO target. BBS News [Internet] 2021. Dec 31, [cited 2021 Jul 9]. Available from: https://www.bbc.com/news/56100076 .
- 19.Africa CDC. COVID 19 vaccine perceptions: a 15 country study [Internet] Addis Ababa: African Union; 2021. [cited 2021 Jul 9]. Available from: https://africacdc.org/download/covid-19-vaccine-perceptions-a-15-country-study/ [Google Scholar]
- 20.Hager E, Odetokun IA, Bolarinwa O, Zainab A, Okechukwu O, Al-Mustapha AI. Knowledge, attitude, and perceptions towards the 2019 coronavirus pandemic: a bi-national survey in Africa. PLoS One. 2020;15:e0236918. doi: 10.1371/journal.pone.0236918. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Kelen GD, Maragakis L. COVID-19 vaccines: myth versus fact [Internet] Baltimore (MD): Johns Hopkins Medicine; 2021. [cited 2021 Jul 9]. Available from: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/covid-19-vaccines-myth-versus-fact . [Google Scholar]
- 22.Verger P, Dube E. Restoring confidence in vaccines in the COVID-19 era. Expert Rev Vaccines. 2020;19:991–993. doi: 10.1080/14760584.2020.1825945. [DOI] [PubMed] [Google Scholar]
- 23.Shen AK. Finding a way to address a wicked problem: vaccines, vaccination, and a shared understanding. Hum Vaccin Immunother. 2020;16:1030–1033. doi: 10.1080/21645515.2019.1695458. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Kata A. Anti-vaccine activists, Web 2.0, and the postmodern paradigm: an overview of tactics and tropes used online by the anti-vaccination movement. Vaccine. 2012;30:3778–3789. doi: 10.1016/j.vaccine.2011.11.112. [DOI] [PubMed] [Google Scholar]
- 25.Betsch C, Brewer NT, Brocard P, et al. Opportunities and challenges of Web 2.0 for vaccination decisions. Vaccine. 2012;30:3727–3733. doi: 10.1016/j.vaccine.2012.02.025. [DOI] [PubMed] [Google Scholar]
- 26.Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021;225:303. doi: 10.1016/j.ajog.2021.03.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Centers for Disease Control and Prevention. COVID-19 Vaccines While Pregnant or Breastfeeding [Internet] Atlanta (GA): Centers for Disease Control and Prevention; 2021. [cited 2021 Jul 9]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html . [Google Scholar]
- 28.Riley LE, Beigi R, et al. American College of Obstetricians and Gynecologists’ Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group. COVID-19 vaccination considerations for obstetric–gynecologic care [Internet] Washington (DC): American College of Obstetricians and Gynecologists; 2021. [cited 2021 Jul 8]. Available from: https://www.acog.org/en/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care . [Google Scholar]
- 29.Society for Maternal-Fetal Medicine. COVID-19 vaccines and pregnancy [Internet] Washington (DC): Society for Maternal-Fetal Medicine; [cited 2021 Jul 8]. Available from: https://www.highriskpregnancyinfo.org/covid-19-pregnancy . [Google Scholar]
- 30.Kim YC, Dema B, Reyes-Sandoval A. COVID-19 vaccines: breaking record times to first-in-human trials. NPJ Vaccines. 2020;5:34. doi: 10.1038/s41541-020-0188-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice Framework for equitable allocation of COVID-19 vaccine [Internet] Washington (DC): National Academies Press; 2020. [cited 2021 Jul 8]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562672/ [PubMed] [Google Scholar]
- 32.Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol Ther. 2019;27:757–772. doi: 10.1016/j.ymthe.2019.01.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines: a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261–279. doi: 10.1038/nrd.2017.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Glanville D. COVID-19 vaccines: development, evaluation, approval and monitoring [Internet] Amsterdam: European Medicines Agency; 2020. [cited 2021 Jul 8]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-development-evaluation-approval-monitoring . [Google Scholar]
- 36.Anyiam-Osigwe T. What you need to know about COVID-19 vaccine approvals in Nigeria and South Africa [Internet] Washington (DC): GAVI; 2020. [cited 2021 Jul 9]. Available from: https://www.gavi.org/vaccineswork/what-you-need-know-about-covid-19-vaccine-approvals-nigeria-and-south-africa . [Google Scholar]
- 37.Ghana Food and Drugs Authority. Safetywatch update no.1: COVID-19 vaccine safety monitoring update [Internet] Accra: Ghana Food and Drugs Authority; 2021. [cited 2021 Jul 9]. Available from: http://fdaghana.gov.gh/news-media.php?page=78 . [Google Scholar]
- 38.Al-Mohaithef M, Padhi BK. Determinants of COVID-19 vaccine acceptance in Saudi Arabia: a web-based national survey. J Multidiscip Healthc. 2020;13:1657–1663. doi: 10.2147/JMDH.S276771. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.World Health Organization. COVAX Joint Statement: call to action to equip COVAX to deliver 2 billion doses in 2021 [Internet] Geneva: World Health Organization; 2021. [cited 2021 Jul 9]. Available from: https://www.who.int/news/item/27-05-2021-covax-joint-statement-call-to-action-to-equip-covax-to-deliver-2-billion-doses-in-2021 . [Google Scholar]